Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection -The European Perspective
NCT02287012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 248
Last updated 2016-10-07
Summary
This study aims to observe the effects of the availability of plerixafor on the time and effort associated with autologous peripheral blood stem cell collection.
Conditions
Interventions
- OTHER
-
Time/Motion evaluation of actual apheresis
The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
Sponsors & Collaborators
-
Pr Mohamad MOHTY
lead OTHER
Principal Investigators
-
Mohamad Mohty, MD, PhD · Hôpital Saint-Antoine
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-10-31
More Related Trials
-
Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)
NCT02662920 ·Status: COMPLETED
-
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
NCT01065129 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
NCT06616636 ·Status: RECRUITING ·Phase: PHASE1
-
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
NCT02320656 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
NCT07047183 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
NCT02189824 ·Status: UNKNOWN ·Phase: PHASE1
-
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia
NCT02842112 ·Status: COMPLETED
-
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
NCT01392079 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
NCT00781170 ·Status: COMPLETED ·Phase: PHASE2
-
Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients
NCT05528354 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
NCT02067143 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
NCT05457010 ·Status: RECRUITING ·Phase: PHASE1
-
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
NCT03735446 ·Status: TERMINATED ·Phase: PHASE1
-
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
NCT04061239 ·Status: RECRUITING ·Phase: PHASE2
-
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
NCT03837171 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
NCT05709093 ·Status: TERMINATED ·Phase: PHASE3
-
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)
NCT03801005 ·Status: COMPLETED
-
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
NCT01653106 ·Status: COMPLETED ·Phase: NA
-
Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
NCT06845592 ·Status: RECRUITING ·Phase: NA
-
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
NCT00186381 ·Status: COMPLETED ·Phase: PHASE2
-
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
NCT06060782 ·Status: RECRUITING ·Phase: PHASE1
-
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT06598969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
NCT03072043 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
NCT05583552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia
NCT07062250 ·Status: RECRUITING ·Phase: NA